- Home
- DAWN vs DCOM Comparison
DAWN vs DCOM Comparison
Compare DAWN & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- DCOM
- Stock Information
- Founded
- DAWN 2018
- DCOM 1864
- Country
- DAWN United States
- DCOM United States
- Employees
- DAWN N/A
- DCOM N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- DAWN Health Care
- DCOM Finance
- Exchange
- DAWN Nasdaq
- DCOM Nasdaq
- Market Cap
- DAWN 1.2B
- DCOM 1.2B
- IPO Year
- DAWN 2021
- DCOM 1996
- Fundamental
- Price
- DAWN $8.07
- DCOM $27.65
- Analyst Decision
- DAWN Strong Buy
- DCOM Buy
- Analyst Count
- DAWN 7
- DCOM 4
- Target Price
- DAWN $32.29
- DCOM $35.50
- AVG Volume (30 Days)
- DAWN 1.3M
- DCOM 284.9K
- Earning Date
- DAWN 05-05-2025
- DCOM 04-22-2025
- Dividend Yield
- DAWN N/A
- DCOM 3.64%
- EPS Growth
- DAWN N/A
- DCOM N/A
- EPS
- DAWN N/A
- DCOM 0.55
- Revenue
- DAWN $131,161,000.00
- DCOM $277,986,000.00
- Revenue This Year
- DAWN $28.72
- DCOM $50.86
- Revenue Next Year
- DAWN $73.78
- DCOM $15.62
- P/E Ratio
- DAWN N/A
- DCOM $51.33
- Revenue Growth
- DAWN N/A
- DCOM N/A
- 52 Week Low
- DAWN $7.88
- DCOM $17.49
- 52 Week High
- DAWN $18.07
- DCOM $37.60
- Technical
- Relative Strength Index (RSI)
- DAWN 36.05
- DCOM 37.50
- Support Level
- DAWN $7.93
- DCOM $27.82
- Resistance Level
- DAWN $8.44
- DCOM $29.32
- Average True Range (ATR)
- DAWN 0.44
- DCOM 0.86
- MACD
- DAWN 0.09
- DCOM 0.10
- Stochastic Oscillator
- DAWN 17.59
- DCOM 36.50
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.